Chronic Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Chronic Myeloid Leukemia Treatment Landscape @ Chronic Myeloid Leukemia Pipeline Outlook
Key Takeaways from the Chronic Myeloid Leukemia Pipeline Report
On 15 August 2025, M.D. Anderson Cancer Center conducted a phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are types of genetic mutations (changes). Chemotherapy drugs, such as ASTX727, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 and dasatinib may help to control Philadelphia chromosome-positive chronic myeloid leukemia or BCR-ABL positive chronic myeloid leukemia in chronic phase.
On 13 August 2025, Novartis Pharmaceuticals announced a study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).
DelveInsight's Chronic Myeloid Leukemia pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Chronic Myeloid Leukemia treatment.
The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others.
Promising Chronic Myeloid Leukemia Pipeline Therapies such as Imatinib mesyl, Dasatinib, Nilotinib, decitabine (5-aza-2'deoxycytidine), Asciminib, Bosutinib, Peginterferon alfa-2a, and others.
Discover groundbreaking developments in Chronic Myeloid Leukemia Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Chronic Myeloid Leukemia Ongoing Clinical Trials Assessment
Chronic Myeloid Leukemia Emerging Drugs Profile
Navtemadlin : Kartos Therapeutics
Navtemadlin (KRT-232) is a novel, potent, and selective oral MDM2 inhibitor. Currently, the drug is undergoing an Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML).
Ropeginterferon alfa 2b : AOP Orphan Pharmaceuticals
Ropeginterferon alfa-2b was discovered by PharmaEssentia Corp. based in Taiwan. BESREMi (Ropeginterferon alfa-2b) is a novel, long-acting, mono-pegylated proline interferon .Its pharmacokinetic properties offer a new level of tolerability.
The Chronic Myeloid Leukemia Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Myeloid Leukemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Myeloid Leukemia Treatment.
Chronic Myeloid Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Myeloid Leukemia market
Stay informed about the Chronic Myeloid Leukemia pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Chronic Myeloid Leukemia Unmet Needs
Chronic Myeloid Leukemia Companies
Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others.
Chronic Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type
Chronic Myeloid Leukemia Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Product Type
Transform your understanding of the Chronic Myeloid Leukemia Pipeline! See the latest progress in drug development and clinical research @ Chronic Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives
Scope of the Chronic Myeloid Leukemia Pipeline Report
Coverage- Global
Chronic Myeloid Leukemia Companies- Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others.
Chronic Myeloid Leukemia Pipeline Therapies- Imatinib mesyl, Dasatinib, Nilotinib, decitabine (5-aza-2'deoxycytidine), Asciminib, Bosutinib, Peginterferon alfa-2a, and others.
Chronic Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Chronic Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research–Access the Full Chronic Myeloid Leukemia Pipeline Analysis Today! @ Chronic Myeloid Leukemia Drugs and Companies
Table of Contents
Introduction
Executive Summary
Chronic Myeloid Leukaemia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chronic Myeloid Leukaemia– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug Name : Company Name
Mid Stage Products (Phase I/ II)
Navtemadlin: Kartos Therapeutics
Early Stage Products (Phase I)
Drug Name: Company Name
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Chronic Myeloid Leukaemia Key Companies
Chronic Myeloid Leukaemia Key Products
Chronic Myeloid Leukaemia- Unmet Needs
Chronic Myeloid Leukaemia- Market Drivers and Barriers
Chronic Myeloid Leukaemia- Future Perspectives and Conclusion
Chronic Myeloid Leukaemia Analyst Views
Chronic Myeloid Leukaemia Key Companies
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Why UnitedHealth Stock Dipped Today After Bumping Higher Monday
Key Points One pundit tracking the stock became less bullish on its future. He knocked down his price target by 37%. 10 stocks we like better than UnitedHealth Group › What the stock analysis community giveth, it can also taketh away. That was the dynamic behind the slide of UnitedHealth Group (NYSE: UNH) stock on Tuesday. As in the previous trading session, the big insurer was affected by an analyst's price target move. This time, however, this took the form of a cut rather than a raise. UnitedHealth closed the day down by 1.5% in value, a worse showing than the S&P 500 's (SNPINDEX: ^GSPC) 0.6% decrease. A chop from a bull The analyst behind the slice was Lance Wilkes from Bernstein SocGen Group. Well before the market open Tuesday, Wilkes took a powerful weed whacker to his UnitedHealth fair value assessment, reducing it to $377 per share; formerly, he believed it was worth as much as $594. Despite the rather drastic adjustment, he maintained his recommendation of outperform (buy, in other words). According to reports, Wilkes wrote in his UnitedHealth update that he expects the company's performance to remain weak through this year, and has commensurately reduced his earnings estimate and target P/E. For the former, he cut his per-share profitability for full-year 2026 by 13%, and for the latter to 12.5 from the preceding 18. The analyst also cited sluggish growth in the insurer's key OptumHealth unit as a reason for his price target cut. Warren likes it UnitedHealth has landed on many an investor's radar following news last week that Berkshire Hathaway had plonked down $1.6 billion for a stake in the company. Anytime Warren Buffett 's investment vehicle buys (or sells, for that matter) a pack of stock for its equity portfolio, the target company becomes a lightning rod for investors. Buffett and Berkshire surely see a company that has potential to reach. Others might consider it something of a clunky underperformer that's fairly -- or even overly -- valued these days. Should you invest $1,000 in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025
Globe and Mail
an hour ago
- Globe and Mail
GitLab: A Risky Investment in a Competitive Software Landscape?
Explore the exciting world of Gitlab (NASDAQ: GTLB) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Jul. 23, 2025. The video was published on Aug. 19, 2025. Should you invest $1,000 in GitLab right now? Before you buy stock in GitLab, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GitLab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025
CTV News
an hour ago
- CTV News
White House starts TikTok account as platform in U.S. legal limbo
The White House is seen, Monday, Aug. 18, 2025, in Washington. WASHINGTON — The White House launched a TikTok account on Tuesday, as U.S. President Donald Trump continues to permit the Chinese-owned platform to operate in the United States despite a law requiring its sale. 'America we are BACK! What's up TikTok?' read a caption on the account's first post on the popular video sharing app, a 27-second clip. The account had about 4,500 followers an hour after posting the video. Trump's personal account on TikTok meanwhile has 110.1 million followers, though his last post was on November 5, 2024 -- Election Day. TikTok is owned by China-based internet company ByteDance. A federal law requiring TikTok's sale or ban on national security grounds was due to take effect the day before Trump's inauguration on January 20. But the Republican, whose 2024 election campaign relied heavily on social media and who has said he is fond of TikTok, put the ban on pause. In mid-June Trump extended a deadline for the popular video-sharing app by another 90 days to find a non-Chinese buyer or be banned in the United States. That extension is due to expire in mid-September. While Trump had long supported a ban or divestment, he reversed his position and vowed to defend the platform -- which boasts almost two billion global users -- after coming to believe it helped him win young voters' support in the November election. Trump's official account on X, formerly Twitter, has 108.5 million followers -- though his favored social media outlet is Truth Social, which he owns, where he has 10.6 million followers. The official White House accounts on X and Instagram have 2.4 million and 9.3 million followers, respectively.
